SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Want to see SIGA full AI Analyst Report?
SIGA Stock Chart & Stats
$6.77
-$0.07(-1.11%)
At close: 4:00 PM EST
$6.77
-$0.07(-1.11%)
Day’s Range― - ―
52-Week Range$4.10 - $9.62
Previous CloseN/A
Volume59.56K
Average Volume (3M)461.52K
Market Cap
$309.85M
Enterprise Value$164.21M
Total Cash (Recent Filing)$145.56M
Total Debt (Recent Filing)$638.23K
Price to Earnings (P/E)15.3
Beta1.46
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding71,724,100
10 Day Avg. Volume376,632
30 Day Avg. Volume461,516
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio10.15
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda5.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$66.31M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And No DebtA ~ $146M cash balance and zero debt provide multi-quarter runway for operations, R&D and manufacturing scale-up. This financial flexibility supports contract fulfilment, strategic partnerships or dividends, and materially reduces refinancing risk amid episodic revenues.
Positive Operating And Free Cash FlowPositive operating and free cash flow on a TTM basis shows the business generates real cash from product deliveries and services. Sustainable cash generation funds working capital, supports production and pipeline activity, and reduces reliance on external financing.
Pipeline Progress (pediatric And PEP)A filed pediatric IND, an active Phase 1 study and a targeted FDA PEP submission within 12 months materially expand long-term commercial optionality beyond stockpile sales. Clinical progress improves future market diversification and supports durable revenue channels if approved.
Bears Say
Sharp Revenue Declines And Lumpy SalesSteep recent revenue declines and episodic deliveries reflect heavy dependence on government procurement and stockpiling. This lumpy demand pattern reduces predictability for capacity utilization, R&D prioritization and margin stability, complicating multi-period planning.
Large TTM Net Loss And Negative Net MarginAn outsized TTM net loss that overwhelms historical operating profitability creates persistent earnings volatility. Even with positive cash flow, recurring or structural losses could erode investor confidence, impair return metrics, and limit reinvestment capacity if not resolved.
Regulatory Setback And U.S. Contract DragThe CHMP recommendation to withdraw the MPOXX indication in Europe reduces near-term European commercialization prospects and adds implementation complexity. Slower progress toward a new U.S. government contract further prolongs revenue uncertainty from core purchasers.
SIGA Technologies News
SIGA FAQ
What was SIGA Technologies Inc’s price range in the past 12 months?
SIGA Technologies Inc lowest stock price was $4.09 and its highest was $9.62 in the past 12 months.
What is SIGA Technologies Inc’s market cap?
SIGA Technologies Inc’s market cap is $309.85M.
When is SIGA Technologies Inc’s upcoming earnings report date?
SIGA Technologies Inc’s upcoming earnings report date is Jul 30, 2026 which is in 40 days.
How were SIGA Technologies Inc’s earnings last quarter?
SIGA Technologies Inc released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is SIGA Technologies Inc overvalued?
According to Wall Street analysts SIGA Technologies Inc’s price is currently Overvalued.
Does SIGA Technologies Inc pay dividends?
SIGA Technologies Inc pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on SIGA Technologies Inc dividends here
What is SIGA Technologies Inc’s EPS estimate?
SIGA Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SIGA Technologies Inc have?
SIGA Technologies Inc has 71,724,100 shares outstanding.
What happened to SIGA Technologies Inc’s price movement after its last earnings report?
SIGA Technologies Inc reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.48%.
Which hedge fund is a major shareholder of SIGA Technologies Inc?
Currently, no hedge funds are holding shares in SIGA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SIGA Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 132.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.66%
12-Months-Change
Fundamentals
Return on Equity
10.62%
Trailing 12-Months
Asset Growth
-11.20%
Trailing 12-Months
Company Description
SIGA Technologies Inc
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
SIGA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.View all SIGA earnings summariesTechnical Analysis
Ownership Overview
1.75% Insiders
12.53% Mutual Funds
11.30% Other Institutional Investors
63.53% Public Companies and
Individual Investors